胃分泌抑制薬の世界市場レポート 2025年

胃分泌抑制薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.1％で199億7,000万米ドルに成長します。予測期間中に予測される成長は、胃腸障害の有病率の増加、高齢者人口の増加、消化器系の健康に対する意識の高まり、ヘルスケアインフラの拡大、ファストフードや加工食品の消費量の増加によってもたらされます。予測期間中に予想される主な動向としては、NSAIDsの普及、抗脂漏薬のOTC販売拡大、ドラッグデリバリー・システムの技術的発展、ジェネリック医薬品の利用可能性拡大、併用療法開発の進展などが挙げられます。

胃腸障害の有病率の増加は、胃分泌抑制薬市場の拡大を牽引すると予想されます。胃腸障害は、胃、腸、関連臓器などの消化管に影響を及ぼし、疼痛、腹部膨満感、便通の変化などの症状を引き起こします。これらの疾患の増加は、不健康な食習慣、特に加工食品の多量摂取と食物繊維の低摂取に起因するところが大きく、これらは腸内細菌叢を乱し、消化を損なう。胃酸分泌抑制薬は、胃酸過多による消化管の損傷を防ぐ上で重要な役割を果たしています。胃酸の分泌を抑えることで、消化器官を保護する粘膜を刺激や損傷から守ることができます。例えば、米国を拠点とする書誌データベースScienceDirectが2025年5月に発表した報告書によると、2022年には約2,350万件の胃内視鏡検査が実施されたことが明らかになりました。このように、消化器疾患の有病率の上昇は、胃分泌抑制薬市場の成長を大きく促進すると予想されています。

胃分泌抑制薬市場の主要企業は、より長期の緩和を提供するために、新しい分泌抑制化合物などの先進製品の開発に注力しています。これらの化合物は、特定の細胞経路や受容体への標的作用を通じて胃酸の分泌を減少または抑制することで機能します。例えば、インドに本社を置くアクムス・ドラッグ・アンド・ファーマシューティカルズ社は2024年6月、消化器系患者向けに設計された新剤形であるラベプラゾール＋レボスルピリドSRカプセルを発売しました。本製剤は、強力な胃分泌抑制作用を有し、胃壁細胞のH+/K+ATPaseを阻害するラベプラゾールナトリウムと、中枢性の抗ドーパミン作用および制吐作用を有するレボスルピリドを配合したものです。本カプセルは、40mgの腸溶性ラベプラゾールと75mgの徐放性レボスルピリドを含有しており、標的を絞った長時間の治療効果を発揮します。その2つの作用機序は、酸抑制と消化管運動調節の両方に対応します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の胃分泌抑制薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の胃分泌抑制薬市場：成長率分析
• 世界の胃分泌抑制薬市場の実績：規模と成長、2019年～2024年
• 世界の胃分泌抑制薬市場の予測：規模と成長、2024年～2029年、2034年
• 世界の胃分泌抑制薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の胃分泌抑制薬市場：薬剤クラス別、実績と予測、2019年～2024年、2024年～2029年、2034年
• プロトンポンプ阻害剤（PPI）
• H2受容体拮抗薬
• 制酸剤
• プロスタグランジン類似体
• 世界の胃分泌抑制薬市場：投与経路別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 経口
• 静脈内
• 局所
• 世界の胃分泌抑制薬市場：流通チャネル別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• その他の流通チャネル
• 世界の胃分泌抑制薬市場：用途別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 胃食道逆流症
• 消化性潰瘍
• ゾリンジャー・エリソン症候群
• その他の用途
• 世界の胃分泌抑制薬市場、プロトンポンプ阻害剤（PPI）の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• オメプラゾール
• エソメプラゾール
• ランソプラゾール
• パントプラゾール
• ラベプラゾール
• デクスランソプラゾール
• 世界の胃分泌抑制薬市場、H2受容体拮抗薬の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• ラニチジン
• ファモチジン
• シメチジン
• ニザチジン
• 世界の胃分泌抑制薬市場、制酸剤の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• 水酸化マグネシウム
• 炭酸カルシウム
• 水酸化アルミニウム
• 重炭酸ナトリウム
• 複合制酸剤
• 世界の胃分泌抑制薬市場、プロスタグランジン類似体のタイプ別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• ミソプロストール
• エンプロスティル

第7章 地域別・国別分析

• 世界の胃分泌抑制薬市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 世界の胃分泌抑制薬市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 胃分泌抑制薬市場：競合情勢
• 胃分泌抑制薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Takeda Pharmaceutical Company Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Sun Pharmaceutical Industries Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Dr. Reddy's Laboratories
• Chemo Biological
• Spansules Pharmatech Pvt. Ltd.
• Phoenix Biologicals Pvt. Ltd.
• Centurion Remedies Private Limited
• Solitaire Pharmacia Pvt. Ltd.
• Shreeji Pharma International
• Estrellas Life Sciences Private Limited
• 3s Corporation
• Actiza Pharmaceutical Private Limited
• Lark Laboratories
• Cytonova Labs International Private Limited
• Luckys Pharma Lab Pvt. Ltd.
• Lexicare Pharma Pvt. Ltd.
• Mustcure Healthcare LLP

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 胃分泌抑制薬市場2029年：新たな機会を提供する国
• 胃分泌抑制薬市場2029年：新たな機会を提供するセグメント
• 胃分泌抑制薬市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

A gastric antisecretory drug is a medication intended to reduce the production of gastric acid in the stomach. These drugs act by inhibiting specific pathways or receptors that stimulate acid secretion, thereby lowering the acidity of stomach contents. By maintaining a more neutral pH in the gastric environment, these drugs help protect the stomach lining and support digestive health.

The primary drug classes of gastric antisecretory drugs include proton pump inhibitors (PPIs), H2 receptor antagonists, antacids, and prostaglandin analogs. Proton pump inhibitors (PPIs) work by irreversibly inhibiting the enzyme H+/K+-ATPase in the gastric parietal cells, thereby effectively reducing acid production. These medications can be administered via oral, intravenous, or topical routes and are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels. They are used to treat conditions such as gastroesophageal reflux disease (GERD), peptic ulcer disease, Zollinger-Ellison syndrome, and related disorders.

The gastric antisecretory drug market research report is one of a series of new reports from The Business Research Company that provides gastric antisecretory drug market statistics, including gastric antisecretory drug industry global market size, regional shares, competitors with a gastric antisecretory drug market share, detailed gastric antisecretory drug market segments, market trends and opportunities, and any further data you may need to thrive in the gastric antisecretory drug industry. This gastric antisecretory drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gastric antisecretory drug market size has grown strongly in recent years. It will grow from $14.87 billion in 2024 to $15.78 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth during the historic period can be attributed to factors such as rising stress levels and sedentary lifestyles, an increase in Helicobacter pylori infections, supportive government healthcare policies, the rise of medical tourism, and the expansion of e-commerce and online pharmacy platforms.

The gastric antisecretory drug market size is expected to see strong growth in the next few years. It will grow to $19.97 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The projected growth during the forecast period is driven by the increasing prevalence of gastrointestinal disorders, a growing geriatric population, rising awareness about digestive health, expanding healthcare infrastructure, and higher consumption of fast and processed foods. Key trends expected in the forecast period include the widespread use of NSAIDs, greater over-the-counter (OTC) availability of antisecretory drugs, technological advancements in drug delivery systems, increased availability of generic alternatives, and progress in combination therapy development.

The growing prevalence of gastrointestinal disorders is expected to drive the expansion of the gastric antisecretory drug market. Gastrointestinal disorders affect the digestive tract, including the stomach, intestines, and related organs, causing symptoms such as pain, bloating, and changes in bowel movements. The increase in these disorders is largely attributed to unhealthy dietary habits, particularly high intake of processed foods and low fiber consumption, which disrupt the gut microbiota and impair digestion. Gastric antisecretory drugs play a crucial role in preventing damage to the gastrointestinal tract caused by excessive stomach acid. By reducing acid production, these drugs help protect the protective lining of the digestive system from irritation or injury. For example, a report published in May 2025 by ScienceDirect, a US-based bibliographic database, revealed that around 23.5 million gastrointestinal endoscopies were performed in 2022. As such, the rising prevalence of gastrointestinal disorders is expected to significantly drive the growth of the gastric antisecretory drug market.

Major companies in the gastric antisecretory drug market are focusing on developing advanced products, such as new antisecretory compounds, to offer longer-lasting relief. These compounds work by reducing or inhibiting the secretion of gastric acid through targeted actions on specific cellular pathways or receptors. For example, in June 2024, Akums Drugs and Pharmaceuticals, an India-based company, launched Rabeprazole + Levosulpiride SR Capsules, a new formulation designed for gastrointestinal patients. This formulation combines rabeprazole sodium, a potent antisecretory agent that inhibits the H+/K+ ATPase in gastric parietal cells, with levosulpiride, which has central antidopaminergic and antiemetic effects. The capsule delivers 40 mg of enteric-coated rabeprazole and 75 mg of sustained-release levosulpiride, providing targeted and prolonged therapeutic action. Its dual mechanism of action addresses both acid suppression and gastrointestinal motility regulation.

In June 2022, Glenmark Pharmaceuticals Inc., an India-based pharmaceutical company, acquired approved Abbreviated New Drug Applications (ANDAs) from Wockhardt Limited for an undisclosed amount. This acquisition enables Glenmark to strengthen its presence in the U.S. market by adding key products such as Famotidine, Cetirizine Hydrochloride, Lansoprazole, and Olopatadine Hydrochloride to its portfolio. Wockhardt Limited is a manufacturer of gastric antisecretory drugs based in India.

Major players in the gastric antisecretory drug market are Pfizer Inc., Bayer AG, AstraZeneca plc, Takeda Pharmaceutical Company Ltd., Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Chemo Biological, Spansules Pharmatech Pvt. Ltd., Phoenix Biologicals Pvt. Ltd., Centurion Remedies Private Limited, Solitaire Pharmacia Pvt. Ltd., Shreeji Pharma International, Estrellas Life Sciences Private Limited, 3s Corporation, Actiza Pharmaceutical Private Limited, Lark Laboratories, Cytonova Labs International Private Limited, Luckys Pharma Lab Pvt. Ltd., Lexicare Pharma Pvt. Ltd., Mustcure Healthcare LLP.

North America was the largest region in the gastric antisecretory drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gastric antisecretory drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gastric antisecretory drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gastric antisecretory drug market consists of sales of mucosal protective agents, digestive enzyme supplements, probiotics for gut health, and controlled-release formulations. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gastric Antisecretory Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gastric antisecretory drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gastric antisecretory drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gastric antisecretory drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Proton Pump Inhibitors (PPIs); H2 Receptor Antagonists; Antacids; Prostaglandin Analogs
• 2) By Route Of Administration: Oral; Intravenous; Topical
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
• 4) By Application: Gastroesophageal Reflux Disease; Peptic Ulcer Disease; Zollinger-Ellison Syndrome; Other Applications
• Subsegments:
• 1) By Proton Pump Inhibitors (PPIs): Omeprazole; Esomeprazole; Lansoprazole; Pantoprazole; Rabeprazole; Dexlansoprazole
• 2)By H2 Receptor Antagonists: Ranitidine; Famotidine; Cimetidine; Nizatidine
• 3) By Antacids: Magnesium Hydroxide; Calcium Carbonate; Aluminum Hydroxide; Sodium Bicarbonate; Combination Antacids
• 4) By Prostaglandin Analogs: Misoprostol; Enprostil
• Companies Mentioned: Pfizer Inc.; Bayer AG; AstraZeneca plc; Takeda Pharmaceutical Company Ltd.; Sun Pharmaceutical Industries
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Gastric Antisecretory Drug Market Characteristics

3. Gastric Antisecretory Drug Market Trends And Strategies

4. Gastric Antisecretory Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Gastric Antisecretory Drug Growth Analysis And Strategic Analysis Framework

• 5.1. Global Gastric Antisecretory Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Gastric Antisecretory Drug Market Growth Rate Analysis
• 5.4. Global Gastric Antisecretory Drug Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Gastric Antisecretory Drug Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Gastric Antisecretory Drug Total Addressable Market (TAM)

6. Gastric Antisecretory Drug Market Segmentation

• 6.1. Global Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Proton Pump Inhibitors (PPIs)
• H2 Receptor Antagonists
• Antacids
• Prostaglandin Analogs
• 6.2. Global Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• Topical
• 6.3. Global Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels
• 6.4. Global Gastric Antisecretory Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gastroesophageal Reflux Disease
• Peptic Ulcer Disease
• Zollinger-Ellison Syndrome
• Other Applications
• 6.5. Global Gastric Antisecretory Drug Market, Sub-Segmentation Of Proton Pump Inhibitors (PPIs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Omeprazole
• Esomeprazole
• Lansoprazole
• Pantoprazole
• Rabeprazole
• Dexlansoprazole
• 6.6. Global Gastric Antisecretory Drug Market, Sub-Segmentation Of H2 Receptor Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ranitidine
• Famotidine
• Cimetidine
• Nizatidine
• 6.7. Global Gastric Antisecretory Drug Market, Sub-Segmentation Of Antacids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Magnesium Hydroxide
• Calcium Carbonate
• Aluminum Hydroxide
• Sodium Bicarbonate
• Combination Antacids
• 6.8. Global Gastric Antisecretory Drug Market, Sub-Segmentation Of Prostaglandin Analogs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Misoprostol
• Enprostil

7. Gastric Antisecretory Drug Market Regional And Country Analysis

• 7.1. Global Gastric Antisecretory Drug Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Gastric Antisecretory Drug Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Gastric Antisecretory Drug Market

• 8.1. Asia-Pacific Gastric Antisecretory Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Gastric Antisecretory Drug Market

• 9.1. China Gastric Antisecretory Drug Market Overview
• 9.2. China Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Gastric Antisecretory Drug Market

• 10.1. India Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Gastric Antisecretory Drug Market

• 11.1. Japan Gastric Antisecretory Drug Market Overview
• 11.2. Japan Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Gastric Antisecretory Drug Market

• 12.1. Australia Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Gastric Antisecretory Drug Market

• 13.1. Indonesia Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Gastric Antisecretory Drug Market

• 14.1. South Korea Gastric Antisecretory Drug Market Overview
• 14.2. South Korea Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Gastric Antisecretory Drug Market

• 15.1. Western Europe Gastric Antisecretory Drug Market Overview
• 15.2. Western Europe Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Gastric Antisecretory Drug Market

• 16.1. UK Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Gastric Antisecretory Drug Market

• 17.1. Germany Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Gastric Antisecretory Drug Market

• 18.1. France Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Gastric Antisecretory Drug Market

• 19.1. Italy Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Gastric Antisecretory Drug Market

• 20.1. Spain Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Gastric Antisecretory Drug Market

• 21.1. Eastern Europe Gastric Antisecretory Drug Market Overview
• 21.2. Eastern Europe Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Gastric Antisecretory Drug Market

• 22.1. Russia Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Gastric Antisecretory Drug Market

• 23.1. North America Gastric Antisecretory Drug Market Overview
• 23.2. North America Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Gastric Antisecretory Drug Market

• 24.1. USA Gastric Antisecretory Drug Market Overview
• 24.2. USA Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Gastric Antisecretory Drug Market

• 25.1. Canada Gastric Antisecretory Drug Market Overview
• 25.2. Canada Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Gastric Antisecretory Drug Market

• 26.1. South America Gastric Antisecretory Drug Market Overview
• 26.2. South America Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Gastric Antisecretory Drug Market

• 27.1. Brazil Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Gastric Antisecretory Drug Market

• 28.1. Middle East Gastric Antisecretory Drug Market Overview
• 28.2. Middle East Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Gastric Antisecretory Drug Market

• 29.1. Africa Gastric Antisecretory Drug Market Overview
• 29.2. Africa Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Gastric Antisecretory Drug Market Competitive Landscape And Company Profiles

• 30.1. Gastric Antisecretory Drug Market Competitive Landscape
• 30.2. Gastric Antisecretory Drug Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Takeda Pharmaceutical Company Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sun Pharmaceutical Industries Overview, Products and Services, Strategy and Financial Analysis

31. Gastric Antisecretory Drug Market Other Major And Innovative Companies

• 31.1. Dr. Reddy's Laboratories
• 31.2. Chemo Biological
• 31.3. Spansules Pharmatech Pvt. Ltd.
• 31.4. Phoenix Biologicals Pvt. Ltd.
• 31.5. Centurion Remedies Private Limited
• 31.6. Solitaire Pharmacia Pvt. Ltd.
• 31.7. Shreeji Pharma International
• 31.8. Estrellas Life Sciences Private Limited
• 31.9. 3s Corporation
• 31.10. Actiza Pharmaceutical Private Limited
• 31.11. Lark Laboratories
• 31.12. Cytonova Labs International Private Limited
• 31.13. Luckys Pharma Lab Pvt. Ltd.
• 31.14. Lexicare Pharma Pvt. Ltd.
• 31.15. Mustcure Healthcare LLP

32. Global Gastric Antisecretory Drug Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Gastric Antisecretory Drug Market

34. Recent Developments In The Gastric Antisecretory Drug Market

35. Gastric Antisecretory Drug Market High Potential Countries, Segments and Strategies

• 35.1 Gastric Antisecretory Drug Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Gastric Antisecretory Drug Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Gastric Antisecretory Drug Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer